STRECK, INC. – Trademark Portfolio
Entity Type: 03
STRECK, INC. owns a portfolio of 72 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as ARM-D, STATS, PARA 4, STRECK, and PARA 12. Of these, 36 are registered. The portfolio spans 7 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 1 (Chemicals). Headquartered in Omaha, NE.
P.O. Box 45625
Omaha, NE 68145
Showing of trademarks Trademarks
Trademark Classifications
STRECK, INC.'s trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does STRECK, INC. have?
STRECK, INC. has 72 U.S. trademarks filed with the USPTO. Of these, 36 registered, 12 abandoned, 24 cancelled.
What trademark classes does STRECK, INC. file in?
STRECK, INC. files trademarks across 7 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are STRECK, INC.'s most well-known trademarks?
STRECK, INC.'s registered trademark portfolio includes well-known marks such as ARM-D, STATS, PARA 4, STRECK, and PARA 12. These are among 36 currently registered trademarks in the portfolio.
What is STRECK, INC.'s trademark registration success rate?
STRECK, INC. has a 50% trademark registration rate, with 36 out of 72 resolved applications resulting in successful registration. Currently, 0 applications are pending review.